Joseph Lobacki

Joseph M. Lobacki brings more than 35 years of biopharmaceutical leadership experience to Artax. Prior to Artax, Mr. Lobacki most recently served as Executive Vice President and Chief Commercial Officer for Verastem, Inc., a biopharmaceutical company. Previous experience includes Chief Operating Officer of Finch Therapeutics Group, and Chief Commercial Officer and Executive Council Member of Medivation, where he was responsible for the strategy and execution of commercial operations including leading a period of strong revenue growth for Xtandi, a treatment for advanced prostate cancer. Mr. Lobacki also held previous roles as Senior Vice President and Chief Commercial Officer of Micromet Inc., where he led all commercial activities including medical affairs and strategic marketing. Prior to joining Micromet, Mr. Lobacki was Senior Vice President and General Manager at Genzyme Corporation, where he managed the launches of Mozobil and Clolar/Evoltra in the US and EU. Mr. Lobacki served as a director of Celator Pharmaceuticals, a public company acquired by Jazz Pharmaceuticals in 2016, and is currently on the board of Sutro Biopharma. Mr. Lobacki holds a Bachelor of Science in Biology from Boston College and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy in Boston.